Getinge AB stock (SE0000202624): investors eye margins and hospital demand after latest quarterly update

Medical-technology group Getinge AB has updated investors with fresh quarterly figures and comments on hospital demand, keeping the focus on margins, order intake and cash flow in a challenging healthcare spending environment.

Medical-technology company Getinge AB has recently reported new quarterly figures and updated investors on demand trends in its core hospital and life-science markets, keeping attention on profitability, order intake and cash generation in a mixed environment for healthcare capital spending, according to the company’s latest results release and accompanying disclosures from spring 2026.

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Getinge AB
• Sector/industry: Medical technology, hospital equipment
• Headquarters/country: Gothenburg, Sweden
• Core markets: Hospitals, intensive care, surgical workflows, life science labs
• Key revenue drivers: Ventilators, operating-room equipment, sterilization and infection-control solutions, cardiovascular devices
• Home exchange/listing venue: Nasdaq Stockholm (ticker: GETI B)
• Trading currency: Swedish krona (SEK)

Getinge AB: core business model

Getinge AB is a Sweden-based medical-technology group focused on products and services that support hospitals, intensive care units and life-science laboratories. The company operates globally and generates a significant share of its revenue from equipment used in operating rooms, intensive care and infection control, targeting both public and private healthcare providers.

The business is typically organized into segments such as acute-care therapies, surgical workflows and life science solutions, covering everything from advanced ventilators and extracorporeal circulation systems to sterilizers and washer-disinfectors. This mix gives Getinge exposure not only to recurring consumables and service contracts but also to more cyclical capital equipment spending by hospitals and clinics.

Through this portfolio, Getinge positions itself as a full-solution provider around critical care and infection control, areas that gained global visibility during the COVID-19 pandemic. The group’s strategy has in recent years emphasized innovation in intensive care monitoring, digital workflow tools and productivity-enhancing service offerings, all aimed at supporting hospital efficiency and patient outcomes.

Main revenue and product drivers for Getinge AB

Revenue at Getinge is largely driven by demand for advanced equipment in intensive care units and operating rooms, including ventilators, anesthesia workstations and other acute-care devices. Hospitals typically commit to multi-year use of such systems, often paired with service and maintenance contracts that provide recurring income streams alongside the initial capital sale.

Another key pillar for the company is its sterilization and infection-control portfolio, which includes washer-disinfectors, sterilizers, low-temperature sterilization systems and related consumables. These solutions are critical for central sterile services departments at hospitals and for certain life-science laboratories, helping to ensure that instruments and equipment meet strict hygiene and safety standards.

In addition to equipment and consumables, Getinge generates revenue through service, retrofits and software solutions that support workflow management in operating rooms and sterile departments. Service revenue tends to be more resilient across economic cycles, while capital equipment orders can fluctuate with hospital investment budgets, reimbursement trends and broader macroeconomic conditions.

Conclusion

Getinge AB remains a globally active supplier of critical hospital and infection-control technology, with earnings and cash flow closely tied to hospital investment cycles and ongoing demand for intensive care and sterilization solutions. For US-focused investors, the stock offers exposure to European healthcare infrastructure and capital equipment dynamics via its listing in Stockholm. The balance between cyclical capital sales and recurring service and consumables income remains central to how the market may assess the company’s resilience and long-term value potential.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.